During the 2016 Chicago Midwinter Meeting, Oravital Inc. will launch its BiofilmDNA oral microbial salivary test, which detects the presence and thresholds of specific pathogens via collected salivary, subgingival, and tongue biofilm samples.
Oravital Inc., the manufacturer of the Oravital System for the diagnosis and treatment of periodontal disease and halitosis, will be making its debut at the Chicago Midwinter Dental Meeting at the McCormick Convention Center at Booth No. 4537 from February 25–27. During this time, the company will also unveil the BiofilmDNA oral microbial salivary test.
BiofilmDNA is a sensitive DNA test that detects both the presence and thresholds of specific pathogens via collected salivary, subgingival, and tongue biofilm samples. This advanced and accurate biofilm analysis provides the dental clinician with a detailed, multipanel, whole-mouth picture of the patient’s oral health.
Oravital’s new BiofilmDNA test is a complement to its BiofilmGS test, which uses site-specific Gram-stain analysis to determine the exact type and location of oral infection. Both the BiofilmDNA and BiofilmGS tests are analyzed in Oravital’s on-site, state-of-the-art lab facility. Reports are available within two days of Oravital’s receipt of the samples. Used together, the two biofilm tests will help the dental clinician accurately identify periodontal disease pathogens, opportunistic parasites, caries pathogens, yeasts, and inflammatory response.
According to company president and CEO Dr. Jim Hyland, “The Oravital System effectively closes the diagnosis/treatment loop by identifying the exact cause and location of oral infection, then providing a highly effective regimen of antibiotic and antimicrobial rinses specifically prescribed for the patient’s personal diagnosis.”
Throughout the Chicago Midwinter Meeting, the company will offer show specials. In addition, Dr. Hyland, DDS, BSc; Chief Science Officer Anne Bosy, RRDH, MEd, MSc; and Clinical Hygiene Educator Kerry Lepicek, RDH, will be available to explain the the proprietary Oravital System, which involves steps for diagnosis, treatment, evaluation, maintenance, and monitoring.
“Undiagnosed and untreated oral infections are a North American epidemic,” explained Hyland. “We also know that periodontal disease is a contributing factor to many systemic conditions, such as cardiovascular disease, diabetes, and Alzheimer’s disease, because the infection spreads via both tissues and the bloodstream. With the introduction of BiofilmDNA, now more than ever, the Oravital system can have a positive impact on not just the oral health, but the overall health of the patient.”